Table 2 Baseline characteristics of the full analysis set population

From: Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy

 

Ad26/MVA

Ad26/Ad26 + gp140

Placebo

All subjects

Analysis set: full analysis set

10

9

6

25

Age, years

N

10

9

6

25

Mean (SD)

42.1 (10.25)

37.9 (9.71)

44.8 (11.39)

41.2 (10.28)

Median (min; max)

44.5 (28;58)

39.0 (29;59)

47.5 (30;56)

41.0 (28;59)

Sex

N

10

9

6

25

Female

0

1 (11.1%)

2 (33.3%)

3 (12.0%)

Male

10 (100.0%)

8 (88.9%)

4 (66.7%)

22 (88.0%)

Race

N

9

7

6

22

Asian

1 (11.1%)

0

0

1 (4.5%)

Black or African American

0

0

1 (16.7%)

1 (4.5%)

Native Hawaiian or Other Pacific Islander

0

1 (14.3%)

0

1 (4.5%)

White

8 (88.9%)

6 (85.7%)

5 (83.3%)

19 (86.4%)

Ethnicity

N

9

9

6

24

Hispanic or Latino

4 (44.4%)

3 (33.3%)

2 (33.3%)

9 (37.5%)

Not Hispanic or Latino

5 (55.6%)

6 (66.7%)

4 (66.7%)

15 (62.5%)

Weight, kg

N

10

9

6

25

Mean (SD)

78.4 (8.06)

82.0 (17.76)

100.6 (19.00)

85.0 (16.95)

Median (min; max)

75.9 (68.3;93.3)

80.6 (62.2;121.2)

99.9 (74.8;128.4)

82.1 (62.2;128.4)

Height, cm

N

10

9

6

25

Mean (SD)

175.7 (4.83)

175.6 (6.96)

169.4 (9.85)

174.1 (7.24)

Median (min; max)

175.4 (169.0;185.8)

178.3 (165.4;184.1)

172.0 (152.0;179.7)

175.2 (152.0;185.8)

HIV RNA, copies/mL

N

10

9

6

25

Mean (SD)

21.4 (8.88)

21.2 (8.03)

15.7 (8.16)

20.0 (8.43)

Median (min; max)

19.0 (11;31)

19.0 (11;31)

11.0 (11;31)

19.0 (11;31)

CD4 Cell Count, /uL

N

10

9

6

25

Mean (SD)

695.1 (345.56)

672.7 (131.54)

775.3 (152.18)

706.3 (238.83)

Median (min; max)

566.5 (385;1377)

646.0 (521;895)

773.0 (521;950)

654.0 (385;1377)

Duration on current ART

N

10

9

6

25

Mean (SD)

1.573 (0.9509)

4.593 (6.1450)

1.244 (0.6480)

2.581 (3.9245)

Median (min; max)

1.235 (0.71; 3.25)

2.519 (0.82; 20.36)

0.976 (0.68; 2.22)

1.251 (0.68; 20.36)

Back to article page